WisdomTree, Inc. (WT): debt financing — WisdomTree issues $475M of 4.625% convertible notes due 2030, net proceeds ~$464M

WisdomTree, Inc.

Issued $475M principal of 4.625% Convertible Senior Notes due Aug 15, 2030; net proceeds ~$464M.
Initial conversion price ~$19.1545 per share (52.2071 shares per $1,000); maximum 75.7003 shares per $1,000.
Notes are senior unsecured, rank equally with existing 3.25% notes due 2026/2029 and 5.75% notes due 2028.
Company may redeem notes on/after Aug 20, 2027 if stock >=130% of conversion price for 20/30 days.
Interest payable semiannually Feb 15 and Aug 15, starting Feb 15, 2026; no sinking fund.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

WisdomTree, Inc. incurred convertible notes of $475.0 million with Oppenheimer & Co. Inc., as representative of the Initial Purchasers at 4.625% maturing August 15, 2030.

Instrument: convertible notes
Principal: $475.0 million
Counterparty: Oppenheimer & Co. Inc., as representative of the Initial Purchasers
Rate: 4.625%
Maturity: August 15, 2030
Event: incurrence

Exact text from the filing

On August 14, 2025, WisdomTree, Inc. (the “Company”) issued $475.0 million in aggregate principal amount of 4.625% Convertible Senior Notes due 2030 (the “Notes”) pursuant to an Indenture (the “Indenture”), dated August 14, 2025, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), in a private offering to qualified institutional buyers (the “Notes Offering”) pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

View on SEC.gov

Browse all debt financings →

WisdomTree, Inc. filing history →

Source: SEC EDGAR

accession 0001214659-25-012285

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.